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variability in CERs for same drugs for different indications, in some cases also varying 
by biomarkers. Primary care drugs had lower and less variable CERs than specialty 
drugs. Variations also exist in methodology used by different groups in modeling cost 
effectiveness, especially for time horizon and comparator. Majority of primary care 
drugs were modeled for a time horizon of 35–40 years or lifetime to demonstrate cost 
effectiveness. Among the top 10 drugs, quetiapine and erythropoietin had the highest 
variability across different studies, and atorvatstatin, salmetrol/ﬂuticasone and clopi-
dogrel had the most consistent ICER values across studies. CONCLUSIONS: This 
analysis shows the range, variability and methods used for calculation of ICER values 
for these high budget impact drugs and provides lessons for executives and policy 
makers.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Patient-Reported 
Outcomes Studies
PMC17
A COMPARISON OF THE DISCRIMINTATIVE AND EVALUATIVE 
PROPERTIES OF THE SF-36 AND THE SF-6D INDEX
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OBJECTIVES: To examine whether the move from the SF-36 to the SF-6D entails a 
loss in discriminative and evaluative strengths, the magnitude of that loss and whether 
it matters. METHODS: The study used relative validity (RV); a ratio of two F statis-
tics, and standardized response means (SRM) to evaluate sensitivity and responsive-
ness of the SF-36 scales and SF-6D index. An RV of 1 reﬂected the most sensitive/
responsive scale and the smaller the RV the less sensitive the measure would be. 
Cohen’s criterion for interpreting effect sizes was used to interpret the SRMs. The 
data used were initially collected for prior studies in seven diseases/conditions: chronic 
obstructive pulmonary disease, leg ulcers, the elderly in exercise, osteoarthritis, irri-
table bowel syndrome, migraine and obesity. Identiﬁed discriminative and evaluative 
variables were used to compare RVs and SRMs of the SF-36 scales and the SF-6D 
index. The mean RV differences and mean SRMs differences between the SF-36 scales 
and the SF-6D index represented the loss or gain in sensitivity. RESULTS: Data were 
available from a total of 10,089 subjects. No single SF-36 scale consistently had the 
largest RV or SRM, and there was no largest RV or SRM observed for the SF-6D 
index in any condition studied. Comparisons showed the SF-6D index was more 
discriminative with a mean RV difference of 0.09, (95% CI; 0.07 to 0.12) and more 
responsive with a mean SRM difference of 0.08, (95% CI; 0 to 0.16) than the SF-36 
scales. However, based on longitudinal RVs the index was less responsive with a mean 
RV difference of 0.07, (95% CI; 0.01 to 0.15) than the SF-36 scales. CONCLUSIONS: 
Moving from the SF-36 to the SF-6D index entails a loss in evaluative strength and a 
gain in discriminative strength, a loss/gain too small to matter given the merits of 
either instrument.
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ELECTRONIC PRO VERSUS PAPER PRO: WHAT DO THE PATIENTS 
THINK?
Ross J, Marcovitz M
Almac Clinical Technologies, Yardley, PA, USA
OBJECTIVES: To examine patients’ preferences and satisfaction on completing 
Patient Reported Outcome (PRO) assessments in studies that compared paper-admin-
istered to electronic versions. To identify which data collection method patients prefer. 
To explore aspects that makes the PRO experience more positive or negative for 
patients. METHODS: A large literature search was conducted to gather articles that 
utilized ePRO. From that, articles were identiﬁed and reviewed that compared paper 
to ePRO and assessed for patient satisfaction/preferences. RESULTS: 119 articles were 
identiﬁed that utilized ePRO; 26 (21.8%) compared paper to ePRO. Of the 26, 17 
(65.4%) reported on patient satisfaction/preferences. Electronic modalities consisted 
of handheld devices (70.6%), interactive voice response system (IVRS) (phone) (17.6 
%), electronic data capture system (5.9%) and both IVRS and handheld (5.9%). 
Patient satisfaction/preference was assessed through either interviews (41.2%) or 
questionnaires (58.8%). Patients reported preferring ePRO over paper in 88.2% of 
the articles. Positives aspects of paper included: familiarity, not dependent on technol-
ogy that may malfunction and ease of reading. Negative aspects of paper included: 
forgetting to complete and burden. Positive aspects of ePRO included: liked the diary’s 
appearance, convenient, ease of data entry, fast/efﬁcient, saves trees, reminders, overall 
survey experience, more fun/novel, easier on eye, more up-to-date, and comfort in 
handling. Negative aspects of ePRO included: system problems/failures, difﬁculty to 
read, difﬁcult to use, instructions could have been simpler, and inability to change 
reminder time or enter data late. CONCLUSIONS: As PRO are measures that come 
directly from the patients, it is important to identify their preferences and aspects of 
what makes their experiences more positive. These ﬁndings suggest that patients 
overall preferred ePRO and identiﬁed more positive aspects for ePRO. Both positive 
and negative aspects reported are equally valuable in identifying how PRO data col-
lection can be improved to provide patients with the most positive experiences.
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DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE  
IN CHINA
Li M1, Bao Z2, Zhou J2, Luo N3
1China Pharmaceutical University, Nanjing, Jiangsu, China, 2The First Afﬁliated Hospital of 
College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, 3National University of 
Singapore, Singapore, Singapore
OBJECTIVES: Health-related quality of life (HRQoL) instruments used in China are 
mainly from Western countries. Such instruments may not cover all the important 
health dimensions relevant to Chinese people as health is a culture-speciﬁc concept. 
However, there is a paucity of empirical data on what good health is to Chinese 
people. The objective of the current study is to identify health dimensions with which 
Chinese people use to deﬁne health. METHODS: A convenience sample of 200 adult 
Chinese (healthy persons: 80; inpatients: 120) were interviewed face to face. Open 
questions were used to elicit characteristics and life domains of good health. RESULTS: 
Fourteen health dimensions were identiﬁed. The 5 most frequently alluded dimensions 
were: mood (35.5%), absence of disease (33.3%), mobility (25.1%), ability to work 
(22.4%), and eating (17.5%). Other dimensions included vitality, pain or discomfort, 
physical ﬁtness, sleep, freedom, self-care, social relationship, enjoyment, and cogni-
tion. More proportion of healthy persons than patients quoted mood and self-care as 
dimensions of health while more patients emphasized ability to work. Males regarded 
eating as a health dimension more often than females while females quoted self-care 
and social relationship more frequently than males. With regard to age, older persons 
valued ability to work more than younger people while more younger people thought 
absence of pain or discomfort is a characteristic of good health. CONCLUSIONS: 
This study provides useful information for assessing the adequacy of HRQoL instru-
ments developed in Western countries for the Chinese population in China.
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THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D 
VISUAL ANALOGUE SCALE (VAS)
Clough LA, Ashcroft-Jones AJ, Furtado T, Wild D
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: The EQ-5D has been translated into many languages. The Euroqol 
group have recently altered and clariﬁed the VAS scale. The objective of this study 
was to produce translations that are conceptually equivalent to the original and to 
other language versions, ensuring the relevance of the translations within the target 
cultures. METHODS: A standard methodology was employed: 1 forward and 1 back 
translation, review and developer review; or an in-country review and developer 
review; linguistic validation interviews with 8 subjects, a mix of healthy people and 
patients, a second developer review and 2 proofreadings. RESULTS: The translation 
process highlighted numerous cultural and linguistic issues, including: 1) Cognitive 
interviews showed that there was no clear Dutch word for scale, so an explanation 
likening the scale to a thermometer as in the previous 3L VAS was necessary; 2) In 
some cultures ‘mark an X on the scale’ was difﬁcult to render, and had to be amended 
by using alternative verb formations and formatting; 3) Though the new VAS mentions 
only ‘health’, in some languages, it was necessary to use “health state” to avoid confu-
sion, e.g. in Czech “health” alone means “good health.”; 4) In some languages the 
concepts of “health” and “health state” had different temporal associations. In 
Korean, “health” referred to a longer period of time, so “health today” had to be 
expressed by “health state today”; 5) Russian patients understood “health state” as 
the evaluation given by a doctor or test results, therefore “in your opinion” was added. 
CONCLUSIONS: The EQ-5D VAS has been translated and linguistically validated 
using a rigorous translation process. A number of cultural and linguistic issues became 
apparent and were resolved. The measure is now appropriate for use in multinational 
trials.
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OBJECTIVES: Patient-reported outcomes (PRO) have received increasing attention 
from regulatory agencies regarding intended use of the data for promotional labeling 
claims. However, some disease areas and/or regulatory bodies necessitate the use of 
PRO data to substantiate product efﬁcacy for securing approval. Therefore, the 
research objective was to determine how many of the ﬁnal product development guid-
ance available from EMEA and FDA for clinical/medical research indicate PRO as a 
mandatory component of efﬁcacy. METHODS: Final guidance documents from the 
EMEA and FDA were reviewed for mention of PRO. EMEA Guidance documents 
that fell under the following categories were excluded: Clinical Pharmacology and 
Pharmacokinetics, Blood and Blood Forming Organs, Blood products (including 
biotech alternatives), and Herbals. Included in FDA Guidance review were those listed 
under the “Clinical/Medical” heading. The following data were abstracted from each 
guidance: guidance number, name, issue date, disease area, body system classiﬁcation, 
PRO requirement, PRO endpoint hierarchy, and a summary of the PRO language 
included in the guidance. PRO statements were then characterized within each of the 
following categories (yes/no): signs/symptoms, function/feeling, HRQOL, or patient 
global rating. RESULTS: Of the 134 ﬁnal guidance documents reviewed (EMEA = 81, 
FDA = 53), 52 mention PRO (EMEA n = 39; FDA n = 13). Within EMEA, PRO is 
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indicated as primary (n = 5) or secondary (n = 22; of which 4 are secondary 
and/or exploratory) or both (n = 12).The majority of PRO statements are characterized 
as sign and symptom measures followed by HRQOL measures. Within FDA, 5 
required PRO and 8 suggest use of PRO. The majority of PRO statements are 
characterized as sign and symptom measures, followed by measures of function/
feeling. CONCLUSIONS: PRO data in many disease areas are viewed by regulatory 
agencies as supportive evidence of the primary endpoint. PRO data are essential in 
the support of product submissions to regulatory stakeholders, especially within 
EMEA.
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OBJECTIVES: To facilitate international comparison of data, PRO translations must 
be conceptually equivalent to the original and culturally relevant to the target country. 
To assess the relevance of conducting a multi-step process on a PRO translation with 
the aim of using it on an immigrant population speaking that language in a different 
country, we investigated the presence and nature of differences between the 2 language 
versions thus obtained. METHODS: Three translations were compared before and 
after adaptation to the context of a host country: 1) the Turkish and German Turkish 
version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ); 2) the Indian 
Gujarati and UK Gujarati version of the Subject Self Report on Symptoms Worksheet 
(SSRSW); and 3) the Chinese Mandarin and US Mandarin version of the National 
Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25). RESULTS: Six of the 
eight items in the Turkish DTSQ were modiﬁed following cognitive debrieﬁng with 
Turkish speakers in Germany. The Turkish population in Germany tends to use more 
old-fashioned wording which doesn’t reﬂect the original language’s recent evolution. 
All four items in the Gujarati SSRSW needed changing when adapting it to a UK 
context. Some initially translated wording was reverted back to English, or substituted 
with transliterated English terms. In the Mandarin NEI-VFQ-25, out of 29 items, 11 
were modiﬁed when adapting it for the USA. The language used in the initial transla-
tion was considered too basic for the target population in the USA, which tends to 
have a higher level of education. CONCLUSIONS: Immigrant language is affected by 
the host country’s culture and language, and/or by separation from the mother 
country, and is no longer fully comparable with the language in the country of origin. 
Adaptation and cognitive debrieﬁng on immigrant populations in target countries is 
advisable to establish culturally relevant translations.
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A UNIVERSAL SCORING SYSTEM FOR EQ-5D : A VASTLY  
SIMPLER SOLUTION
Kind P
University of York, York, UK
OBJECTIVES: Country-speciﬁc social preference sets have been estimated to support 
the use of EQ-5D in computing QALYs for cost-utility analysis. However these value 
sets have limited applicability in non-economic applications since a) they incorporate 
the state “dead” which is irrelevant in many therapeutic settings, and(b) they are based 
on hypothetical preferences from 3rd parties who may not have any experience of 
speciﬁc EQ-5D health states. This paper reports on the construction of a scoring 
system for EQ-5D based on self-rated VAS values generated by individuals with 
current experience of those states. METHODS: EQ-5D data from several different UK 
sources were pooled yielding a total of 23,679 useable observations. The health state 
deﬁned by each respondent’s self-rated problem level on the 5 EQ-5D dimensions was 
determined, yielding a total of 139 unique EQ-5D health states. The mean VAS rating 
was computed for each of these states. 0/1 dummy variables were deﬁned for each of 
the EQ-5D dimensions and an OLS regression analysis was performed with the mean 
self-rated VAS rating as the dependent variable. RESULTS: The model ﬁtted the mean 
VAS ratings data very well (r2 = 0.985) when forced through the origin. All decrements 
within dimension were monotonic and internally consistent. Residuals were 5 points 
or lower when observed and estimated values were compared. Estimated values for 
all EQ-5D health states were computed so that full health (11111) has a value of 100 
and worst possible health (33333) has a value of 0. CONCLUSIONS: This methodol-
ogy contrasts markedly with the more complex requirements of utility estimation and 
produces a weighting system that can be used to meaningfully report health status. It 
has applicability as a performance measurement tool with real-world interpretability. 
If corresponding data from other countries were included then a single global scoring 
system for EQ-5D could be established.
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OBJECTIVES: To test whether social preferences for allocating health resources are 
affected by the framing of questions METHODS: 162 students from the University 
of Southern California were asked four questions. Each question asked participants 
to select one of two possible treatments with each treatment resulting in a different 
distribution of outcomes for the treated population. After treatment, patients could 
have one of three outcomes: “Good Health”, “Poor Health”, or “Death.” The ﬁrst 
medication listed always had 19 fewer people in “Good Health”, 23 more people in 
“Poor Health” and 4 fewer people in the “Death” state relative to the second medica-
tion listed. The only aspect that varied between questions was the number of patients 
unaffected by treatment choice. Two questions had a “standard frame”, indicative of 
commonly asked questions in the equity literature. The remaining two questions had 
a “sure thing” frame, in which common outcomes between the two treatments were 
made apparent. Frame order was randomized for each of the participants. A key 
qualitative principle behind QALY maximization is that those individuals unaffected 
by a policy choice should not inﬂuence the policy choice. Violations of this principle 
were measured for each of the frames. RESULTS: The proportion of violations of 
QALY maximization (indicated by switched preference) in the “standard” frame was 
0.31 (56/183); while in the “sure-thing” frame, the proportion was 0.08 (15/183). 
The difference between groups was statistically signiﬁcant (p < 0.001) CONCLU-
SIONS: The most common way of asking for preferences for equality tends to foster 
aversion to inequality, which does not support QALY maximization. In contrast, a 
frame that separates common outcomes between choices may occasion preferences 
that maximize QALYs. These results have implications for measurement techniques 
such as the person tradeoff which assumes framing has no effect on preferences for 
health allocation.
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OBJECTIVES: Recognizing that medication non-adherence is a signiﬁcant cause of 
suboptimal health outcomes, the objective of this study was to obtain patient feedback 
on communication with providers and preferences for various adherence tools. 
METHODS: Online cross-sectional survey of patients with: asthma/COPD, allergies, 
bipolar disease, cardiovascular disease, depression, diabetes, multiple sclerosis, osteo-
porosis, pain syndromes, and rheumatoid arthritis. Patients completed close-ended 
questions about the amount of information they received from health care providers; 
the usefulness of various adherence tools in managing their condition; and the impact 
of additional disease/product information. Patient ratings of each adherence tool were 
scored on a scale ranging from 0 (“not at all valuable”) to 3 (“very valuable”). Paired 
t-test was used to compare the preference for explicit adherence reminders (medication 
reminders via email, telephone and SMS text) versus each of the other adherence tools. 
The association of patient preferences for each tool with age was evaluated using 
Pearson correlation coefﬁcients and using one-way analysis of variance (ANOVA) for 
associations with medical conditions, gender, education, family income and health 
insurance source. RESULTS: A total of 642 patients completed the survey. Forty 
percent reported receiving inadequate information from their physician (range: 22% 
for rheumatoid arthritis to 54% for cardiovascular disease). Across medical conditions 
groups, patients preferred adherence tools that conveyed information about medica-
tion dosing, safety, and drug interactions. Explicit adherence reminders were uni-
formly deemed least valuable compared to other adherence tools (all p-values < 0.0001 
based on paired t-tests). There were some differences observed in preferences for 
adherence tools across condition, gender, and age; no signiﬁcant associations were 
found between patient preferences and education level, family income, or source of 
health insurance. CONCLUSIONS: Patients often receive inadequate information 
about their medications and conditions. Medication adherence tools that educate 
patients may simultaneously address their desire for more information and reinforce 
adherence.
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EVALUATING TREATMENT SATISFACTION ENDPOINT EVIDENCE FOR 
EMEA REGULATORY APPROVALS
Nixon A, Quadri N, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: To document the extent to which treatment satisfaction evidence is 
provided in support of EMEA regulatory approvals and to evaluate the quality of 
evidence provided in support of treatment satisfaction claims.METHODS: A review 
of EMEA published reports for all drugs approved since a centralised process was 
established in 1995 was undertaken: speciﬁcally the Scientiﬁc Discussion/Public 
Assessment Reports were reviewed for evaluations of patient-reported treatment sat-
isfaction. The wording and types of PROs contained within approved product labels 
were examined in order to establish the nature and extent of previous successful claims 
for treatment satisfaction.RESULTS: A total of 508 currently authorised medicinal 
product approvals were reviewed, 26 made reference to ‘satisfaction’ or ‘satisﬁed’ but 
9 were excluded for not focusing on patient-reported treatment satisfaction thus 17 
medicinal products were identiﬁed as having a direct reference to evaluating patient-
reported treatment satisfaction. These 17 approvals ranged from July 1998 to July 
2008, and were distributed across a broad range of pharmaco-therapeutic groups with 
a cluster of approvals for ‘insulin analogues for injection, long lasting’ (n = 4): 10/17 
approvals provided limited reference to the way in which treatment satisfaction was 
evaluated e.g. reference to a total satisfaction score without any further details, 2/17 
measured treatment satisfaction using a VAS; 5/17 referenced a speciﬁc treatment 
satisfaction measure. 5/17 provided treatment satisfaction of results, yet only two of 
these gave any details on the way in which treatment satisfaction was measured. 
